Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen the Target of One Class-Action Suit, Not Two

NEW YORK, Dec. 12 (GenomeWeb News) - Ciphergen Biosystems is the target of a class-action suit by one law firm, not two, for allegedly misleading shareholders.

 

GenomeWeb News incorrectly reported last week that Ciphergen was named in a second class-action lawsuit alleging that the company and certain of its officers and directors misled shareholders. In fact, the company is being sued by one law firm, Kaplan Fox & Kilsheimer, which disclosed its class-action complaint on Dec. 5.

 

The Kaplan Fox & Kilsheimer suit, filed in the United States District Court for the Northern District of California, alleges Ciphergen issued a series of "false and misleading statements" regarding its financial condition between Aug. 8 and Nov. 16.

 

On Aug. 8, Ciphergen released its second-quarter earnings. On Nov. 6, the company said that its audit committee is investigating the recognition of around $500,000 in sales recorded in that quarter. As a result, the company, which has enlisted the help of undisclosed "external accounting advisors," said it would delay the release of its third-quarter financial results.

 

On Nov. 16, Ciphergen disclosed that its audit committee had determined that the company's  second-quarter results need to be restated and could not be trusted.

 

The restatement would reduce the quarter's reported revenue by 7 percent, or $503,000, and increase reported net loss by 3 percent, or $301,000, Ciphergen said at the time.

 

The suit claims that Ciphergen's original second-quarter financial results, which reported a 10-percent slide in revenue and a 30-percent increase in losses, artificially inflated share prices, and that when the company publicized its audit committee's findings, the stock plummeted 21percent, from $1.73 to $1.36 per share.

 

Investors who purchased Ciphergen' stock between Aug. 8 and Nov. 16 are covered under the class-action status, according to Kaplan Fox & Kilsheimer.

 

Shares in Ciphergen have fallen around 30 percent since news of the suit broke. The stock was trading down 11.7 percent, or $.11, at $.83 in mid-afternoon trading today, which is the stock's 52-week low.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.